DNA repair pathways and human cancer

The Molecular Basis of Cancer

Volumn , Issue , 2008, Pages 39-55

  D'Andrea, Alan D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58749104937     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603703-3.10004-4     Document Type: Chapter

References (66)

1. Lengauer C, Kinzler KW, Vogelstein B Genetic instabilities in human cancers. Nature 1998, 396:643.
2. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000, 100:57-70.
3. Cleaver JE Defective repair replication of DNA in xeroderma pigmentosum. Nature 1968, 218:652.
4. Cleaver JE Xeroderma pigmentosum: a human disease in which an initial stage of DNA repair is defective. Proc Natl Acad Sci U S A 1969, 63:428.
5. Surralles J, Jackson SP, Jasin M, Kastan MB, West SC, Joenje H Molecular cross-talk among chromosome fragility syndromes. Genes Dev 2004, 18:1359.
6. Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem 2006, 281:30305-30309.
7. Friedberg EC, Lehmann AR, Fuchs RP Trading places: how do DNA polymerases switch during translesion DNA synthesis?. Mol Cell 2005, 18:499.
8. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006, 34:633.
9. Nojima K, Hochegger H, Saberi A, et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 2005, 65:11704-11711.
10. Friedberg EC. DNA damage and repair. Nature 2003, 421:436.
11. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913.
12. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917.
13. Wilson SH, Sobol RW, Beard WA, Horton JK, Prasad R, Vande Berg BJ. DNA polymerase beta and mammalian base excision repair. Cold Spring Harb Symp Quant Biol 2000, 65:143.
14. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001, 1:22.
15. Lieber MR, Ma Y, Pannicke U, Schwarz K Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003, 4:712.
16. Fischhaber PL, Friedberg EC How are specialized (low-fidelity) eukaryotic polymerases selected and switched with high-fidelity polymerases during translesion DNA synthesis?. DNA Repair (Amst) 2005, 4:279.
17. McCulloch SD, Kunkel TA Measuring the fidelity of translesion DNA synthesis. Methods Enzymol 2006, 408:341.
18. Steinacher R, Schar P. Functionality of human thymine DNA glycosylase requires SUMO-regulated changes in protein conformation. Curr Biol 2005, 15:616.
19. Ulrich HD. SUMO modification: wrestling with protein conformation. Curr Biol 2005, 15:R257.
20. Sugasawa K. UV-induced ubiquitylation of XPC complex, the UV-DDB-ubiquitin ligase complex, and DNA repair. J Mol Histol 2006, 37:189.
21. Huang TT, D'Andrea AD Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol 2006, 7:323.
22. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, Lieberman J. Gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell 2005, 20:801.
23. Nijman SM, Huang TT, Dirac AM, et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005, 17:331.
24. Huang TT, Nijman SM, Mirchandani KD, et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol 2006, 8:339.
25. Rothfuss A, Grompe M. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol 2004, 24:123.
26. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316.
27. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499.
28. Bakkenist CJ, Kastan MB. Initiating cellular stress responses. Cell 2004, 118:9.
29. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410:842.
30. Sorensen CS, Syljuasen RG, Falck J, et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003, 3:247.
31. Nakamura A, Sedelnikova OA, Redon C, et al. Techniques for gamma-H2AX detection. Methods Enzymol 2006, 409:236.
32. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol 2004, 6:168.
33. Manke IA, Lowery DM, Nguyen A, Yaffe MB BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 2003, 302:636.
34. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho- protein binding domain. Science 2003, 302:639.
35. Celeste A, Petersen S, Romanienko PJ, et al. Genomic instability in mice lacking histone H2AX. Science 2002, 296:922.
36. Franco S, Gostissa M, Zha S, et al. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell 2006, 21:201.
37. Sorensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005, 7:195.
38. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004, 18:1958.
39. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864.
40. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633.
41. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907.
42. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006, 24:3799.
43. Giglia-Mari G, Coin F, Ranish JA, et al. A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiodystrophy group A. Nat Genet 2004, 36:714.
44. Kennedy RD, D'Andrea AD The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005, 19:2925.
45. Taniguchi T, D'Andrea AD Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006, 107:4223.
46. Boudsocq F, Benaim P, Canitrot Y, et al. Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. Mol Pharmacol 2005, 67:1485.
47. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross)linked to DNA repair. Cell 2005, 123:1191.
48. Lord CJ, Garrett MD, Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res 2006, 12:4463.
49. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006, 66:8109.
50. Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005, 70:139.
51. Sanchez-Perez I. DNA repair inhibitors in cancer treatment. Clin Transl Oncol 2006, 8:642.
52. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004, 64:9152.
53. Syljuasen RG, Sorensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation. Cancer Res 2004, 64:9035.
54. Chirnomas D, Taniguchi T, de la Vega M, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006, 5:952.
55. Szabo CI, King MC Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997, 60:1013.
56. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66.
57. Gudmundsdottir K, Ashworth A The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25:5864.
58. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997, 90:425.
59. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88:265.
60. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 1999, 96:11364-11369.
61. Yu X, Fu S, Lai M, Baer R, Chen J BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev 2006, 20:1721.
62. Burr KL, Velasco-Miguel S, Duvvuri VS, McDaniel LD, Friedberg EC, Dubrova YE Elevated mutation rates in the germline of Polkappa mutant male mice. DNA Repair (Amst) 2006, 5:860.
63. Sweasy JB, Lang T, DiMaio D Is base excision repair a tumor suppressor mechanism?. Cell Cycle 2006, 5:250.
64. Sweasy JB, Lauper JM, Eckert KA DNA polymerases and human diseases. Radiat Res 2006, 166:693.
65. Bagby GC, Olson SB Cisplatin and the sensitive. Cell Nat Med 2003, 9:513.
66. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983.